BBIO BridgeBio Pharma

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

PALO ALTO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 11 AM (ET).



The presentation will be webcast live and can be accessed at  on the For Investors page under News & Events. The webcast will be available for replay through August 12, 2020.



About BridgeBio

BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.



Investor Contact:

John Grimaldi, Burns McClellan



212-213-0006 ext. 362



Media contact:

BridgeBio Pharma, Inc.

Grace Rauh



(917) 232-5478



Source: BridgeBio Pharma, Inc.

EN
06/05/2020

Underlying

BBIOBridgeBio Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BridgeBio Pharma

 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 11 new employees in restricted stock units for an aggregate of 23,884 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on...

14h / 47m 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within ...

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM - By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p

September 28, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the compensation committee of its board of directors (the “committee”) approved equity grants in the form of restricted stock units (“RSUs”) to new employees under the Company’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”). The committee approved: (i) on September 5, 2025, RSU grants...

September 10, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

Encaleret Showed Parathyroid Hormone-Independent Normalization of Bloo...

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseline - Encaleret was well-tolerated with no serious adverse events reported over the study period - Based on these findings, BridgeBio intends to initiate a registrational clinical study ...

September 6, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Invest...

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Princip...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch